Q3 2021 Organogenesis Holdings Inc Earnings Call
Good afternoon, ladies and gentlemen, and when it comes to the third quite a tiny tiny one earnings conference call for Gonogenesis Holdings incorporate.
At this time, all participants have been place and listen only mode.
Please note that this conference call is being recorded and that the recording will be available on the company's website for me. Please so I can be.
Before we begin I would like to remind everyone that are you much today make one theme forward looking statements that are based on your current expectations of management and involved in her interests and uncertainties that could cause actual results to differ materially from those indicated including the risks and uncertainties. This guy.
In the company's filings with the Securities and Exchange Commission.
Including item one a risk factors of the company's most recent animal in quite a <unk> quite early reports.
You are cautioned not to place undue reliance upon any forward looking statements.
Which speak only itself did eat made although it may have voluntarily do so from time to time.
The company and it takes no commitment to update or device. The forward looking statements, whether as a result of new information future events or otherwise exec.
Exactly as required by applicable securities laws.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or again please.
We generally refer at their days as non-GAAP financial measures reconciliations of days non-GAAP financial measures do the most comparable measures calculated.
And presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn to call over to Mister Guy ESCO. He knew senior advantage and he says holding <unk> President and Chief Executive Officer. Please go ahead Sir.
Welcome everyone to.
Third quarter of 2021.
From school.
Today, I'm joined and Nicole.
Chief Financial Officer, Dave Francesco.
So let me start with a brief agenda or what will cover during a prepared remarks today.
I'll start with an overview of our financial performance in the third quarter, including a discussion of the key drivers of the strong revenue growth and profitability of team delivered.
Two three.
After my opening remarks, Dave will provide you with a more in depth review of our third quarter financial results.
David guidance for 2021 that we updated in this afternoon's press release, and then we'll open up the call for questions.
Beginning with the review about third quarter revenue performance I'm pleased to report that we didn't delivered another quarter of strong performance.
Wait a tougher than expected operating environment.
During the quarter, we reported revenue growth of 13% year over year to 113.8 million driven by 19% growth.
Advanced wound care products, which you're all set a 41% decrease in the sale of a surgical and sports medicine products as expected a surgical in sports medicine results reflected the headwinds for a renewed new cell product lines. Following the expiration of the FDA enforcement Grace period for those products, which ended on may 3rd.
First of this year.
Excluding net revenue from these products are net revenue increased 20% year over year on and adjusted basis in the third quarter.
A full reconciliation of our non-GAAP adjusted net revenue to GAAP net revenue is included in our earnings release.
A performance in Q3 continues to reflect that strong execution again, so cheap pillars of our growth strategy, which includes leveraging our comprehensive and differentiated portfolio of products diversifying our revenue sources across multiple sites of care physician specialties and leveraging leveraging a broad commercial reach.
Let me provide more color on how each of these long term drivers of growth contributed to our revenues performance. Despite the tougher operating environment in the third quarter.
Regarding the strength of our portfolio, we have a broad portfolio of products across the continuum of wound care with a unique customer value proposition through a combination of our pure applied brand, which is the only skin substitute with purified collagen and ph M. B, a broad spectrum anti microbial or amniotic portfolio.
So with the only fresh amniotic membrane on the market.
PMA approved products for veal use and D F views.
A sale of pure pure applied products increased 39% in the quarter. This growth was driven by strong utilization from existing customers and a contribution from new customers.
Excluding the expected loss of renew and new cell product lines sale of our amniotic products were essentially flat in the third quarter and the sale of our PMA and other products increased 14% year over year in Q3.
Second we continue to diversify our revenue by expanding into new physician specialties and multiple sites of Kid a better position the company for sustained long term growth.
Additionally, we continue to leverage our organogenesis physician solutions platform to further penetrate the office market and as a result, we continue to expand the number of customers and customer accounts in the office channel and we're experiencing increased utilization of our products from existing customers.
Lastly on enhancing our commercial reach we continue to make significant investments to garage sales force and we believe our team of 330 direct sales representatives represents a key competitive advantage for organogenesis.
With respect to the overall operating environment, the third quarter as we highlighted on our queue to call. We expected a measure softness in Q3 growth trends as a result of the seasonality, we typically experience and although we expected to see steady improvement in COVID-19 related headwinds as we moved through the second half of 21, we.
To see more COVID-19 impacts in July and early August in key areas of the country and we will monitoring monitoring it very closely we ultimately did experience it tougher than expected operating environment. In Q3 is healthcare facilities in Covid hot spots around the country implemented restrictions on access which negatively impacted.
Patient consultations treatments and elective procedures, notably commercial strategy in recent years has resulted in a broad diversification of our revenue specifically less exposure to acute care in outpatient settings, which historically have experienced greater COVID-19 related headwinds. However, in the third quarter we experienced.
Spiller of spillover of these COVID-19 related headwinds in the office setting which has in the past been a little more resilient.
A strategic initiatives focused on diversifying our revenue and leveraging a strong product portfolio and it allowed us to drive 20% growth on and adjusted basis in the third quarter, despite tougher operating environment.
We are encouraged by the continue expansion of our customer accounts in the office channel and the growth and utilization of our products from existing customers.
That said the unexpected COVID-19 headwinds had a material impact on a full commercial launch of affinity during the quarter.
Staff shortages increased restrictions and limitations on access challenge our ability to engage with new customers impacting the adoption of our new novel technology, and ultimately had a material impact on sales for our amniotic products in Q3.
As a result of these challenging headwinds as we've done in the past we have success successfully leveraged our diverse portfolio and drove better than expected sales and are purified Brian.
To recap the Chi takeaways for the quarter, we delivered another quarter strong growth against a difficult comparison in the prior year and impressive financial performance, particularly with respect to a strong operating cash flow generation and the period, we ended the quarter with more than $100 million in cash on the balance sheet and Ah.
Team executed well, despite the tough environment, we experienced and we made great progress towards our strategic initiatives.
Long term, we will continue to lead the space launching highly innovative and highly efficacious products as we deliver on our mission to provide integrated healing solutions that substantially improve outcomes and reduces the overall cost of care.
One more item I'd like to address before I turn the call over to David.
We've had recent recently, we've had several inquiries regarding Medicare and not having a published right for affinity in the fourth quarter.
As part of our strategy to grow the brand nationwide and Q1 of this year, we voluntarily reported our ISP for affinity and we're very pleased to receive a published ESP.
Four Q3.
Q for Asp's submission was impacted by a filing era.
Which initially resulted in an incorrect right issued by CMS and ultimately resulted in affinity not having a published rate for the fourth quarter. However, we are confident that the nationally published rate will be reinstated on January 1st 2022.
And contrary to contrary to some speculation in the market affinity continues to be covered and reimbursed by all Max in the fourth quarter with.
With that I'd like to turn the call over to David to review, our financial results in the third quarter, a balance sheet and financial condition and are updated guidance. Thank you Gary I'll begin with a review of our third quarter financial results unless otherwise specified all growth rates referenced during my prepared remarks or on a year over year basis.
Gary mentioned, we are pleased with a strong revenue growth in the quarter, given the challenging environment as well as the prior year comparable.
Net revenue for the third quarter of 2021 was $113 $8 million up 13% and normalizing for the loss of renewing new So we grew adjusted net revenue by 20%.
Our advanced wound care revenue for the third quarter of 2021 was $107.3 million up 19% driven by our expanded sales force and increased adoption of a pure play line extensions launched in the second half of 2020.
Revenue from surgical in sports medicine products of the third quarter of 2021 was $6.4 million down 41% driven by the impact of sales of a renew and new sell products, which we stopped marketing. After may 31, 2021, do the expiration of the Fda's enforcement Grace period.
Revenue from pure apply products for the third quarter of 2021 was $56 $9 million up 39%.
It's Gary indicated earlier, we were pleased with the continued strong performance of of pure play brand as sales have increased 33% year over year over the first nine months of 2021.
Regarding our commercial footprint, we ended the quarter with 330 direct reps and expect to achieve our goal of ending the year with 340 direct representatives compared to 300 as of December 31 2020.
Gross profit for the third quarter of 2021 was 87.6 million, where approximately 77% of revenue compared to 77% last year.
Operating expenses for the third quarter of 2021 was $71.3 million compared to $55 million last year, an increase of $16.3 million or 30%.
The increase in operating expenses in the third quarter was driven by an $11 million increases selling general and administrative expenses and a $5.2 million increase in research and development costs compared to the prior year period.
The year over year increase in selling general and administrative expense was primarily due to a $4.8 million increase related to additional head count primarily in our direct salesforce and increased sales commissions due to the increased sales of $2.3 million increase in marketing travel expenses as compared to the low prior year comparable amid COVID-19 related travel restrictions and the third call.
2020.
Third quarter of 2021, selling general administrative expense also included three items that did not impact our prior year results.
A $1 million of restructuring costs associate with the closing of the Hoya facility.
A $1.1 million right off a certain design and consulting fees previously capitalised related to the unfinished construction work on the 275, Dan Road building.
And is there a point $9 million non-cash benefit related to the change in the fair value of the earn out liability in connection with the CPN acquisition.
The year of your increase in R&D expense was primarily driven by an increase in the clinical study and related costs necessary to seek a regulatory approvals for certain of our products.
Operating income for the third quarter of 2021 was $16.3 million compared to an operating income of $22.8 million last year, a decrease of six $5 million 29%.
Third quarter GAAP operating margin was $14, 3% of net revenue, excluding the aforementioned wreck restructuring costs right off of previously Capitalised construction expenses and the change in the fair value of the earn out liability operating margin was $15, 4% in the third quarter of 2021.
Total other expenses for the third quarter of 2021 were $3.4 million compared to $2 million last year.
An increase of 1.4 million or 71% driven primarily by at 1.9 million dollar loss on extinguishment of debt related to the repayment of our 2019 credit agreement during the period.
Net income for the third quarter of 2021 was $12 $6 million.09, a share compared to net income of $28 million.19 a share.
A decrease of $8 $2 million.10 per share.
Adjusted EBITDA was 21.7 million for the third quarter of 2021, 19% of net revenue compared to adjust EBIT adjusted EBITDA of $24.6 million for 24% of net revenue last year a decrease of <unk>.
We have provided a full reconciliation of our adjusted EBITDA results in our earnings release issued this afternoon.
Turning to the balance sheet as of September 30th 2021, the company out of 102.7 million in cash restricted cash and $83 $2 million in debt obligations of which nine $4 million, where capital lease obligations this compared to $84.8 million in cash and restricted cash and $84 8 million in debt obligations of which 15.
1 million, where capitalized lease obligations as of December 31, 2020.
As mentioned last quarter, we secured a new credit agreement in early August the agreement provides for credit facility in the aggregate amount of $200 million consisting of a $75 million term loan at 125 million revolving credit facility, the new facility reduces our borrowing costs and enhances our financial flexibility.
Along with are improving profitability profile and related cash flow generation as well positioned us to continue to execute on our strategic growth initiatives in the years to come.
Turning to review of our 2021 revenue guidance, which we updated in our press release. This afternoon for 12 months ended December 31, 2021. The company now expects net revenue between $458 million and $470 million, representing an increase of approximately 35% to 39% year over year as compared to net revenue a 300.
$38.3 million for the 12 months ended December 31 2020. This.
This compares to our prior guidance range of $456 million to $472 million.
The 2000 to 2021 net revenue guidance assumes net revenue from advanced wound care products between $425 million and $434 million, representing an increase of approximately 44% to 47% year over year.
This compares to our prior guidance, which call for growth of $44, 48% year over year.
Net revenue from surgical the sports medicine products between $33 million and $36 million, representing a decrease of approximately 18% to 24% year over year unchanged from her prior guidance range net.
Net revenue sales are pure apply products between $196 million and $204 million, representing an increase of approximately 33% to 39% year over year and this compares to our prior guidance range, which called for growth of 22% to 27% year over year.
In addition to the formal revenue guidance, we'd like to provide a few considerations for investors to bear in mind, when evaluating our growth expectations for fiscal year 2021.
This additional color is intended to help the investment community better understand their assumptions supporting our revenue expectations for 2021.
First the largest contributor of our total company net revenue in fiscal year, 2021 will be sales or or any other products, which is the midpoint of our full year total revenue range now assumes amniotic growth of approximately 52% year over year 2021.
This compares to our prior guidance range, which assumed at the midpoint of approximately 68% year over year and reflects our updated expectations for the timing of our full commercial launch of Infinity.
Second we expect sales of our remaining non to reply non amniotic products, which collectively form the group called PMA and other to increase at the mid point of the range at approximately 14% year over year in 2021. This compares to our prior guidance range, which assume growth at the midpoint of approximately 11% year over year, reflecting better than expected performance in the third quarter.
Third we expect to see only modest improvement in cold related headwinds as we move through the fourth quarter. Our guidance now reflects a more challenging operating environment versus art, what our prior guidance at a soup. However, despite the COVID-19 related headwinds in the second half of 2021 are full year guidance reflects the strong growth range of 35% to 39% and remains at the midpoint of our previous guidance of 460.
$4 million or 37%.
As detailed on our prior earnings calls this year. Our guidance also continues to reflect the expectation of lower year over year growth in the second half of 2021 compared to the prior year as highlighted in previous early earnings call. This expectation is driven primarily by two factors.
First the strong performance or advanced wound care business in the second half of 2020, we expect this year year growth trends in the second half of 2021 moderate because we left to 56% growth from the second half of 2022nd.
Second an estimated 18 million headwind to growth over the last seven months of 2021 related to the removal of renew and new cell from the market beginning June 1st 2021.
With our respect with respect to our expectations for financial performance of 2021, we continue to expect to report positive GAAP net income and positive adjusted EBITDA for the fiscal full fiscal year 2021.
In addition to our formal financial guidance for 2021, we're providing some consideration for modeling purposes for the full year 2021 period. We now expect gross margins of approximately 75% total GAAP operating expenses to increase approximately 27% year over year.
Note or 2021 GAAP operating expenses include approximately 5 million of restructuring expenses related to a la Jolla, California facility of which $2.9 million occurred in the first three quarters of 2021.
[noise] non-cash DNA of approximately 10 million non stack non-cash stock comp of approximately $3.5 million weighted average diluted shares of approximately $34 million and we accept expect full year 2021, capex of approximately 30 million of which approximately two thirds is related to growth in gross margin improvement initiatives.
Finally, we expect total interest and other expenses of approximately nine $5 million is a lower borrowing costs assisted with the refinance facilities, partially offset by exit cost expense in the third 2021.
With that operating I'll turn the call back over to you.
If you'd like to ask a question please didn't help <unk>.
Crafting star one on your telephone keypad.
Using a speakerphone please make here yet.
Let me ask you allow your signal alright, alright.
We do ask that give me make yourself to one question and one follow up if you would like to ask a question to be invited to add yourself did it to you again bye passing five one.
And our first question will come from.
Ryan Zimmerman M B P I Z.
Your lifestyle okay.
Everyone I appreciate all the color you gave today on guidance and commentary on CMS, I guess starting with guidance.
For both of you guys.
As we think about the recovery into the fourth quarter you have.
Pier pie kind of going up offsetting some of the smaller amniotic sales specifically due to a phillies delay and so it just help us understand kind of how the wound market is recovering in the fourth quarter and and why you should we should expect to see stronger purify sales, maybe offset in some of the other slower areas like a surgical towards Madison are empty.
<unk>. Thank you.
Sure. So I mean, the environment really is not improving dramatically.
And continue to see the impact of Covid I think for.
Are pure apply products one of the areas. That's really helped the the product is we have more accounts small physician specialties. It's a more established brand and we were able to focus our large salesforce.
On selling.
That product because of its brand equity and because of the customers. We have so we've been able to drive a little extra growth within those existing accounts and some additional account so.
It's really the utility of the products and the focus of our Salesforce, we've done that in the past.
And it.
It is really had an impact David if you have a different opinion I think that's right I mean, it's just as you said, it's a well established brand continues to be something with the customers find a lot of clinical utility in and we continue to see good growth from that product line.
And and just taking a little further than that and I have one follow up but are you seeing.
Offsetting usage of some of the other products are you seeing often usage I guess.
Care apply just given your focus on it relative to potentially other products that are in your portfolio or others and then it's gonna ask hip hop on Afinitor sure. So.
<unk> is a very different product I mean, ultimately all all the products get to a point of healing. So our focus when you're selling affinity excuse me pure apply as it is a different focus it's a different patient. It's a patient earlier on in the process, where affinity is more of a recalcitrant wound later in the process and a <unk>.
Sites of care. So our sales reps will then focus on a dermatologist or a plastic surgeon office.
Where that product pure apply can be utilized where you wouldn't with affinity so.
It really does.
Expand the use of the product there can be some because ultimately the objective is to heal the wounds, but the the type of patient and the sites of care are a little bit different. So we don't expect a significant amount of.
Cannibalization across usage.
I appreciate that and then just.
Lastly for me as we think about affinity I mean, it's been obviously, a subject of investor discussion this quarter and so.
How much of affinity imps.
The impact and guidance that you've laid out how much do you think that that's due to the delay and roll out versus maybe other factors and what impact have you seen in the fourth quarter from CMS is.
Error.
With the Max in terms of utilization and any color you can provide maybe on what kind of their expectation or what they've said or indicated about the plan going forward would be appreciate it. Thank you yeah sure.
So.
CMS has not provided any color he wouldn't discuss any discussions we have with them, but we do expect to get the right.
Re established as I mentioned, so when when we file for a published AFP. When you move to a published ESP you will have a pause and that's considered in our guidance when you.
You move that had published aspca and that pauses related to benefit Verifications and other changes that happened with the product. So you'll have those types of impacts.
You also have the rest of the country, which is the strategy here, where you're not selling the product where you have the opportunity to sell to the entire country and build the brand more broadly and build a base for long term growth. So there are changing dynamics clue.
Clearly when you move to a published ISP, which is again something that we filed for and we believe is in the best interest for the long term growth of the product.
So clearly not being able to get out those new customers in those regions, where we haven't sold the product at all has really had an enormous impact.
You get the benefit of those additional regions.
And you may have some loss in existing regions, but overall you end up in a better place, but we weren't able to get at those new regions and get out those customers.
That's.
A major impact on an affinity for the quarter, David you have and I would agree and that is really all about access and kind of adopting a new technology. So it was really challenging in the period.
Okay. Thank you.
Sure.
Your next question comes from Mcnamee Q.
<unk>. Please your line is open.
Hi, Thanks, guys for taking the question and congrats on a really strong quarter in a tough environment.
Maybe.
I apologize, Gary if I missed it but just because of the questions and focus around reimbursement amount of affinity and.
And pure apply just wondering if you. If you. If you provided if you could provide any color on like the trajectory of growth the cadence of growth.
Second and third quarter, and maybe what your expectations are.
In the fourth quarter.
Understanding guide byproducts like that but just with.
Whether you're expecting things to improve or.
Remain table, just just anything anything you'd be willing to share would be helpful and everyone follow up sure. So we certainly expect.
Sales of affinity to approve in queue for.
Even with the the loss of published ASP, there will be a a pause again.
In October so we expect to see that and we did see that and we are now starting to see the product pick back up once benefit verifications are done and folks understand that.
The product is still being reimbursed. So we feel like that there will be a slight improvement in the product will grow in queue for.
We expect to have published Aspie in January and then we will relaunched the product again in January and we would expect a pause again when you have a change in your ASP and you now have a published ASB, which is different than.
Will be benefit fabrication process, which normally happens in Q1 anyway.
As deductibles reset for our customers. So we do expect that there'll be some pause going into Q1, but ultimately we expect.
<unk> to continue to be a growth driver for the company going forward Okay.
And just maybe to understand the value of the product we spent a fair amount of time.
Making calls out to clinicians about the product early in our diligence and.
Covering the company over the past several years and.
And the feedback has certainly been positive, but I thought it might be helpful. Just for folks to understand.
Given the array of them yet so I'd sit around there Mr. Melendez like what is special about any where is it used that you've maybe would not use the dehydrated did you have the honor.
Just doing a little more color on where where clinicians really seek it and use it.
Particularly I guess in the physician channel on late at this point.
Correct. So it is unique it is the only fresh amnion in the space. So it has.
Living cells in the product similar to many of our other products. That's part of who we are as living active technology. So when it when it wound is recalcitrant, meaning it hasn't really close more than 50%.
And for weeks and.
The clinician is challenged and they feel an active product lake affinity is really what's needed to jumpstart the wound that's really the value of the product.
It's when you have that wound that's really difficult and again the question feels an active.
Living type technology.
Help that wound move.
Move on to healing.
Through the proliferative phase ultimately to healing.
Thanks for that and good luck. Thank you ma'am.
Next question comes from Stephen Mcmanus with Oppenheimer. Your line is open.
Thank you hi, guys.
Gary just on D. A S P U update for the fourth quarter what for January excuse me what gives you the confidence that it will be on the next list I know you mentioned.
Not wanting to talk about any comprehension with CMS, but anything you guys have looked at relative to prior situations or any outside consultants or anything to give you that competence.
Well sure. We certainly have a lot of outside consultants has given us a lot of confidence that that would happen I think it's important to note that we received.
An ASP published ASP for the quarter was just incorrect and.
In the process of trying to get it corrected we didn't meet the timelines and weren't able to get the ASP reestablish. So it was a filing error.
And this happens often.
What we've been told by our consultants is the Max will typically reimburse it and we are seeing that so that's ended up being accurate and then you refile, if you've correctly and it'll get reestablished again. So we have no reason to believe or any reason to believe that it wouldn't be reestablished at this point.
Okay got it.
And then relative to Covid I just wanted to put a final point of what you're seeing out Barry it.
It sounds like you're seeing pretty steady environment versus what you saw in the third quarter and uhm, what part of your business, specifically would see more of an impact versus others. As you mentioned you diversify it a lot. So I'm certainly not all but if you could talk a little bit more color on what's impacted and what you're seeing out there today.
So I mean, our entire business has really impacted what's troubling is when you don't have access and you're launching a new technology like affinity it's challenging because you need multiple meetings you need training.
Punishing typically goes through benefit verification, obviously, and then a trial period with the product. So there's a lot of access that's required so anything that's new or new customers.
Ah more challenged our existing accounts, where we have great brand equity we have great relationships, we're able to continue to sell and go a little deeper which helped your apply this past quarter.
That's really the challenge is branching out with new technologies into new accounts are new physician specialties. When you don't have access.
Got it thanks, very I'll come back in queue.
Thank you.
If you'd like to ask a question. Please signal by passing star one on your telephone keypad.
And we asked taking the media sounds good to one question and one to follow up.
Next question comes from Daniel and Bath, and coffee made S. B B and then your line is open.
Hi, I'm.
I'm sorry, Danielle thanks, so much for taking our question sure yeah.
Uhm so congrats on the corner I, just wanted to kind of dynamic deeper into the copay Hedlund I know you mentioned that that staffing shortages.
Training a challenge I just was hoping to see.
Any way to quantify.
What that impact last night and thank you.
Like you know this is kind of a lack of <unk> that that could potentially Linda I just wanted to kind of get a sense of how this may impact correct. Thanks alright.
February 3rd third quarter was an impact we estimated to be about $4 million I think as you move into Q4, it's a little bit more difficult to tease. It out just because of the components that Gary said about the access this is a change in dynamics and the launch and how much is associated with.
With specific COVID-19 related.
It's a little bit more challenging to tease out here then yes. It is.
But we think there's about 4 million in the third quarter.
But we do that we clearly think thats the headwind is going to exist.
Two four.
We're battling it in navigating it with our portfolio in our in our customers and we also think it could leak into the first half of next year as well based on what we're seeing so.
Okay thinking that as well. Thank you yeah based on kind of color and then on the office down obviously the diversification diversification of care setting has helped you power through them you know somebody to come and have one I just wanted to get it done said how penetrated you.
I wanted the potential of town and you know how much my life potentially left and that channel.
So we don't really provides how many accounts, but what I, what I've said before as the channel as large as about 12000.
Offices and we.
So give us about 6000 high potential offices.
We're not anywhere near.
Penetrating.
That channel significantly underpenetrated.
Okay, great. Thank you so much for taking my question.
My pleasure.
We are currently now we are currently showing knowing meaning questions in the queue at this time.
That conclude that timeframe for today. Thank you for for your for your participation.
Thank you.
[music].
[music].
[music].
[music].
Good afternoon, ladies and gentlemen, and welcome to the third quarter 2021 earnings conference call for a Guy Who's Genesis holdings incorporate.
At this time, all participants have been placed in a listen only mode.
Note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Before we begin I would like to remind everyone that argue much today may contain forward looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated including the risks and uncertainties. This guy.
<unk> in the company's filings with the Securities and Exchange Commission.
Including item one a risk factors of the company's most recent annual and quarterly to quarterly reports.
You're cautioned not to place undue reliance upon any forward looking statements.
Which speak only as of the deep made although it may voluntarily do so from time to time the company undertakes no commitment to update or revise the forward looking statements whether as a result of new information future events or otherwise, except as required by applicable securities laws.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP.
I really refer to as non-GAAP financial measures.
Conciliations of this non-GAAP financial measures due to the most comparable measures calculated.
And presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn the call over to Mr. Gary S. <unk>, SR Organogenesis Holdings, President and Chief Executive Officer. Please go ahead Sir.
Thank you.